Burden of Gastrointestinal, Liver, and Pancreatic Diseases in the United States

Abstract

Background & Aims Gastrointestinal (GI), liver, and pancreatic diseases are a source of substantial morbidity, mortality, and cost in the United States (US). Quantification and statistical analyses of the burden of these diseases are important for researchers, clinicians, policy makers, and public health professionals. We gathered data from national databases to estimate the burden and cost of GI and liver disease in the US. Methods We collected statistics on healthcare utilization in the ambulatory and inpatient setting along with data on cancers and mortality from 2007 through 2012. We included trends in utilization and charges. The most recent data were obtained from the Centers for Disease Control and Prevention, the Agency for Healthcare Research and Quality, and the National Cancer Institute. Results There were 7 million diagnoses of gastroesophageal reflux and almost 4 million diagnoses of hemorrhoids in the ambulatory setting in a year. Functional and motility disorders resulted in nearly 1 million emergency department visits in 2012; most of these visits were for constipation. GI hemorrhage was the most common diagnosis leading to hospitalization, with more than 500,000 discharges in 2012 at a cost of nearly $5 billion dollars. Hospitalizations and associated charges for inflammatory bowel disease, Clostridium difficile infection, and chronic liver disease have increased over the last 20 years. In 2011, there were more than 1 million people in the US living with colorectal cancer. The leading GI cause of death was colorectal cancer, followed by pancreatic and hepatobiliary neoplasms. Conclusions GI and liver diseases are a source of substantial burden and cost in the US.

Enhancing Diagnostic Performance of Symptom-Based Criteria for Irritable Bowel Syndrome by Additional History and Limited Diagnostic Evaluation

“…IBS results in reduced quality of life for the individual, and represents a considerable economic burden to society due, in part, to the costs to healthcare systems of managing the condition. 3 There is an expectation that physicians should try to reduce these costs by making a positive diagnosis of IBS, using symptom-based diagnostic criteria, whilst simultaneously minimizing invasive investigations. 4,5 Physicians may be reluctant to adopt this approach in clinical practice, as GI diseases manifest as a limited repertoire of symptoms, and those of IBS can mimic organic diseases such as inflammatory bowel disease, 6 microscopic colitis, 7 bile acid diarrhea, 8,9 or celiac disease.…”

Cholecystectomy in mild acute biliary pancreatitis: The sooner; the better

“…Acute pancreatitis is the third leading cause of hospital admissions in gastroenterology and its clinical management in the first 72 hours continues to be a clinical challenge (15). Since 1988, more than 30 clinical guidelines and their respective updates have been published.…”

The Bedside Index for Severity in Acute Pancreatitis: a systematic review of prospective studies to determine predictive performance

“…The rate of hospitalization continues to grow [2]. Analysis of national inpatient sample databases showed a 33% increase in acute pancreatitis-related hospitalization over a 7-year period from 1997 to 2003 [3].…”